HONG KONG – Hormones released during chronic stress have been shown to remodel the lymphatic vasculature to promote cancer cell dissemination in mice, while targeting that stress pathway with beta-blockers may prove useful in blocking the spread of cancer cells, Australian scientists report in the March 1, 2016, issue of Nature Communications.
Huya Bioscience International LLC, of San Diego, appointed Akira Miyazato vice president, head of clinical research and development in Japan. His role is to support the company’s advancement of its lead anti-cancer drug HBI-8000 through accelerated development in Japan for lymphoma.
3SBio Inc., of Shenyang, China, said the CFDA approved its investigational new drug application for peg-irinotecan, a long-acting polymer-drug conjugate that inhibits topoisomerase I. Peg-irinotecan was developed by Jenkem Technology Co. Ltd., of Beijing, which inked an exclusive license agreement with 3SBio in 2014 to develop, manufacture and market the candidate in mainland China.
TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company.
HONG KONG – After an 11-month suspension in trading, shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460) plunged more than 54 percent on Monday.
Aslan Pharmaceuticals Pte. Ltd., of Singapore, appointed Andrew Howden an independent non-executive director. Howden is a senior pharmaceutical executive with almost 35 years of experience and has a strong track record in clinical research, business development and commercialisation. Most recently, he was CEO of Inova Pharmaceuticals Pty Ltd., of Thornleigh, Australia, which was acquired by Valeant Pharmaceuticals International Inc., of Laval, Quebec.
Sirtex Medical Ltd., of Sydney, highlighted the publication of results from the SIRFLOX study, a test of SIR-Spheres Y-90 resin microspheres, published online in the Journal of Clinical Oncology. In the primary endpoint of the study, patients with nonresectable liver-dominant or liver-only colorectal cancer who received FOLFOX-based first-line chemotherapy alone had a median progression-free survival (PFS) at any site of 10.2 months vs. 10.7 months in those that received chemotherapy plus SIR-Spheres.
HONG KONG – A green light to launch clinical trials in Canada for one of its leading biosimilar products will give South Korean company Alteogen Inc. and its Brazilian partner a boost on the global market.
NEW DELHI – Start-ups and spin-offs could boost India's biopharma sector, as long as the sector as a whole can overcome a series of hurdles, including a chronic shortage of financing.
RSS